Fox Chase Cancer Center Awarded Philadelphia's First Community Clinical Oncology Program (CCOP) Research Base
PHILADELPHIA (September 2, 2003) — The National Cancer Institute (NCI) has awarded Fox Chase Cancer Center a multi-million dollar grant to serve as a research base for the Community Clinical Oncology Program (CCOP) - the first such institution based program in Philadelphia. The CCOP is a program of the NCI to support research between designated academic cancer centers like Fox Chase and community cancer centers (CCOP affiliates) enabling patients and physicians to participate in NCI clinical trials at 61 major research centers in 34 states across the country, the District of Columbia, and Puerto Rico. Fox Chase Cancer Center has received a three-year grant from the NCI totaling $3.8 million.
Fox Chase Cancer Center has a strong history with the NCI as one of the first cancer centers in the nation to receive the NCI-designation as a Comprehensive Cancer Center in 1974.
"The CCOP research base award will allow more patients to have access state-of-the-art cancer prevention and control studies developed by Fox Chase and its consortium," explained Paul F. Engstrom, MD, FACP senior vice president of population science at Fox Chase. Engstrom is the project principle investigator and the chairman of this new cooperative group.
Fox Chase Cancer Center will serve as the research base, while the other institutions involved in the consortium will aid Fox Chase in developing research ideas and clinical trials for cancer prevention and control. The institutions in the consortium are the University of Pittsburgh Cancer Institute, Thomas Jefferson University Hospital, Roswell Park Cancer Institute and Columbia University.
The goal of the Fox Chase Cancer Center-CCOP research base is to reduce cancer incidence, morbidity and mortality through identification, implementation and evaluation of cancer prevention and control interventions.
To help achieve its goal, Fox Chase Cancer Center has established four modality committees to investigate areas where cancer prevention and control research is needed. The committees are prevention/genetic research, nursing research/supportive care, behavioral research, and epidemiology and outcomes research with the task of coordinating clinical trials for use in the community setting.
"The primary benefit of the CCOP research base is it allows researchers to bring these clinical trials closer to patients' homes and determine results more quickly," adds Engstrom. "The NCI grant provides additional resources to Fox Chase to increase the number of clinical trials for cancer treatment, control and prevention. Equally important, CCOP will allow us to evaluate and measure our intervention efforts."
Clinical trials are research studies conducted with patients or with healthy people. They are designed to answer specific questions about the effectiveness of new ways to prevent, detect, diagnose, and treat cancer.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.